Long-listed products (LLPs) in Japan will be subject to a new health coverage scheme starting this October. This is expected…
BUSINESS
Pfizer to Roll Out JN.1-Adapted COVID Vaccine
Pfizer will launch an updated monovalent version of its COVID-19 vaccine targeting the JN.1 Omicron strain in Japan on September 19, the company and partner BioNTech said on September 18. The vaccine, “Comirnaty intramuscular injection syringe for over 12 years…
To read the full story
Related Article
- Japan Expects COVID Vaccine Supply of 32 Million Doses from 5 Makers in 2024-25
September 3, 2024
- Pfizer Earns Japan Nod for JN.1-Adapted COVID Vaccine
August 9, 2024
BUSINESS
- Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
- UCB CEO Hails Positive Change in Japan’s Pharma Policy
September 19, 2024
- Viatris to Discontinue Nesp Biosimilar after Global Business Sell-Off
September 19, 2024
- Asahi Kasei to Divest Medical Devices Unit to Integral, but Retains Bioprocess Biz
September 19, 2024
- Nippon Shinyaku Set to Expand Capricor DMD Therapy Pact to Europe
September 19, 2024
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…